JM Financial sees 26% upside in Viyash Scientific, citing patent expiries, integration and R&D moat; read why it set a ₹338 target.
Original Image Link
Source:www.financialexpress.com
Original Image Link
Source:www.financialexpress.com
Posted: 2026-07-01 11:48:00

















